Risers & Fallers: Mosman, Vedanta, ReNeuron, Macromac, Lonmin, James Fisher and more...
Here are the main news-driven share price movements at 4pm.
Company
ReNeuron Group PLC
LON:RENE
ReNeuron Group PLC has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several unique and scalable exosome producer cell lines, its CustomEX ™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes.
298 stories · page 15 of 15
Archive
FTSE100 ends higher as new Greek proposal creates optimism
FTSE100 closed out the week over 91 points higher as traders cheered latest moves in Greece.
Archive
Proactive news summary, including fastjet, Hummingbird Resources, Sirius Minerals and Active Energy
A mixed news bag from budget carriers to biotechs..Here are some highlights..
Archive
FTSE 100 celebrates as Greece PM decides game is up
FTSE 100 rose 98 points to 6,680 as Greece PM submitted new debt proposals.
Archive
FTSE 100 surges higher as Greek PM caves in
Tsipras said he had received a mandate in the referendum to negotiate a better deal, not to take the country out of the eurozone.
Investments and investor services
Risers & Fallers: Altona, Igas, ReNeuron, Sefton, Sirius Minerals, Zoltav Resources
It's no surprise that, after two days of stonking gains in Shanghai, Fidelity Special Situations is the best performing FTSE 350 stock.
ReNeuron gets Woodford's backing as it raises £68mln
Olav Hellebø, Renueron’s chief executive, said it is the largest funding by a cell therapy group anywhere this year.
Archive
FTSE100 ends higher as new Greek proposal creates optimism
Investors looked to a brighter future for Greece as its PM Alexis Tsipras submitted a new austerity plan.
Archive
Broker Spotlight – Carnival, SKY, Go-Ahead, Bunzl, Standard Life, Gemfields...
It’ll soon be time for summer holidays, but first City brokers handed out a upgrades in the travel and leisure sector.
Investments and investor services
Proactive news summary: Gemfields, Savannah, ReNeuron, Rambler, Stride, Sierra Rutile and more
It was a busy day in the world of small caps with a lot of companies taming up.
Investments and investor services
Market movers: ReNeuron, Cap-XX, Creightons, Rambler, Gemfields, Styles & Wood
Investors were still buying in after Styles & Wood reported a tripling of underlying profit before tax for 2014 on Friday.
UPDATE - ReNeuron extends collaboration with Australian biotech
ReNeuron's technology appears to offer a delivery mechanism for a gene silencing therapy.
Broker Spotlight – Royal Mail, RBS, Angle Plc, ReNeuron, Sirius Minerals
Here investors can catch up on Thursday's broker views
ReNeuron beefs up management as overseas ambitions grow
Two appointments to strengthen management team as ReNeuron steps up international expansion.
ReNeuron's eye disease treatment placed on fast-track by US regulator
American regulators have recognised the potential ReNeuron’s stem cell treatment for a group of rare eye diseases by granting it fast-track status, according to the company’s chief executive Olav Hellebø.